Zeng Ruolan, Li Bin, Huang Junhui, Zhong Meizuo, Li Li, Duan Chaojun, Zeng Shan, Huang Jin, Liu Wei, Lu Jingchen, Tang Youhong, Zhou Lingming, Liu Yiping, Li Jianhuang, He Zhengxi, Wang Quan, Dai Youyi
Department of Oncology, Xiangya Hospital, Central South University , Changsha, China .
Genet Test Mol Biomarkers. 2017 Nov;21(11):641-648. doi: 10.1089/gtmb.2017.0060. Epub 2017 Sep 14.
Peritoneal carcinomatosis (PC) is an important cause of morbidity and mortality among patients with gastric cancer. Thus, it is important to identify an ideal biomarker for PC.
Plasma and ascites samples were collected from gastric cancer patients with PC and a control group. Lysophosphatidic acid (LPA) levels were tested and analyzed.
The plasma LPA levels of gastric cancer patients with PC were significantly higher than those in gastric cancer patients after radical resection (p = 0.046) and healthy volunteers (p < 0.001). Besides, plasma LPA levels were statistically lower after chemotherapy in gastric cancer patients with PC (p = 0.028). Furthermore, the ascites LPA levels were significantly higher in gastric cancer patients with peritoneal carcinomatosis than those in liver cirrhosis patients (p < 0.001). Moreover, ascites LPA levels were statistically lower after intraperitoneal chemotherapy injection than before (p < 0.001). In addition, the plasma LPA levels were significantly associated with serum CA125 levels (p = 0.032) and TNM stage in gastric cancer patients (p = 0.009). Individuals with plasma LPA levels >20,000 ng/mL had significantly worse overall survival (OS) than those with plasma LPA levels <20,000 ng/mL group (p = 0.006). In addition the group with ascites LPA levels >24,000 ng/mL showed significantly worse progression-free survival (PFS) and OS (p < 0.001 in PFS and OS).
This study demonstrated that LPA levels in plasma and ascites may be useful diagnostic biomarkers for PC of gastric cancer and that higher levels are associated with poor prognosis.
腹膜癌病（PC）是胃癌患者发病和死亡的重要原因。因此，识别PC的理想生物标志物很重要。
收集胃癌伴PC患者及对照组的血浆和腹水样本。检测并分析溶血磷脂酸（LPA）水平。
胃癌伴PC患者的血浆LPA水平显著高于根治性切除术后的胃癌患者（p = 0.046）和健康志愿者（p < 0.001）。此外，胃癌伴PC患者化疗后血浆LPA水平有统计学意义的降低（p = 0.028）。此外，胃癌腹膜癌病患者的腹水LPA水平显著高于肝硬化患者（p < 0.001）。而且，腹腔化疗注射后腹水LPA水平有统计学意义的低于注射前（p < 0.001）。另外，胃癌患者血浆LPA水平与血清CA125水平（p = 0.032）和TNM分期显著相关（p = 0.009）。血浆LPA水平>20,000 ng/mL的个体总生存期（OS）显著差于血浆LPA水平<20,000 ng/mL组（p = 0.006）。此外，腹水LPA水平>24,000 ng/mL组的无进展生存期（PFS）和OS显著更差（PFS和OS中p < 0.001）。
本研究表明，血浆和腹水中的LPA水平可能是胃癌PC的有用诊断生物标志物，且较高水平与预后不良相关。
